Ann: Dr Irminger steps down from Board, continues as Consultant, page-15

Difficult times for the biotechs that aren't fully developed and selling, but then again it always has been for the biotechs until they area established. There is only so much revenue the hTert product can generate, I think, although I am not sure, they are trying to put together a suite of non invasive Ca diagnostic products rather than remain a one trick pony. I assume that the current Sienna product is providing something in terms of cash flow whilst the Bard 1 products go through the final stages in preparation for commercialisation. Once they have 3 to 4 products commercialised and generating revenue then, obviously, it will be les of an issue. I still think there will not be much other than remaining at current levels or a decline in the value of the SP depending on market conditions until mid to late 2021. In the meantime it will be much of the same I suspect. I had assumed the merger/acquisition was more about eventually providing a broad range of complimentary products, establishing sales network pathways whilst generating enough revenue to keep things solvent ....my thoughts, stay well to all